re: PYC targeting Kidney Disease
Here's a really valuable podcast by 'Phase III' titled 'The Silent Killer: Why biotechs are all in on kidney disease'. PYC are mentioned a couple of times. It gives great insight into the kidney disease industry, what types of drugs are in trials and deals done. This episode has Prof Meg Jadine, Director of the NHMRC Clinical Trials Centre and Cris Kallos, healthcare and biotech equities analyst. The podcasts are weekly and our CEO will be on the next one (later this week).
https://phase3.buzzsprout.com/2389069/15518775-the-silent-killer-why-biotechs-are-all-in-on-kidney-disease
Ann: Kidney Disease Drug Candidate Progressing to Human Trials, page-30
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $933.2M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 370000 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 89756 | 2 |
View Market Depth
| Last trade - 16.12pm 21/10/2024 (20 minute delay) ? |
| PYC (ASX) Chart |
Day chart unavailable